BRPI0913590A2 - novos compostos de uracila ou sal dos mesmos tendo uma atividade inibitória deoxiuridina trifosfatase humana - Google Patents

novos compostos de uracila ou sal dos mesmos tendo uma atividade inibitória deoxiuridina trifosfatase humana

Info

Publication number
BRPI0913590A2
BRPI0913590A2 BRPI0913590A BRPI0913590A BRPI0913590A2 BR PI0913590 A2 BRPI0913590 A2 BR PI0913590A2 BR PI0913590 A BRPI0913590 A BR PI0913590A BR PI0913590 A BRPI0913590 A BR PI0913590A BR PI0913590 A2 BRPI0913590 A2 BR PI0913590A2
Authority
BR
Brazil
Prior art keywords
inhibitory activity
salt compounds
deoxyuridine triphosphatase
novel uracil
human deoxyuridine
Prior art date
Application number
BRPI0913590A
Other languages
English (en)
Inventor
Hitoshi Miyakoshi
Junko Taguchi
Masayoshi Fukuoka
Seiji Miyahara
Tatsushi Yokogawa
Wakako Yano
Yayoi Takao
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of BRPI0913590A2 publication Critical patent/BRPI0913590A2/pt
Publication of BRPI0913590B1 publication Critical patent/BRPI0913590B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0913590-1A 2008-06-03 2009-06-02 Composto de uracila ou sal do mesmo tendo uma atividade inibitória de deoxiuridina trifosfatase humana, composição farmacêutica e inibidor dutpase que compreendem o dito composto de uracila e uso terapêutico do mesmo BRPI0913590B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008-146334 2008-06-03
JP2008146334 2008-06-03
PCT/JP2009/002481 WO2009147843A1 (ja) 2008-06-03 2009-06-02 ヒトデオキシウリジントリホスファターゼ阻害活性を有する新規ウラシル化合物又はその塩

Publications (2)

Publication Number Publication Date
BRPI0913590A2 true BRPI0913590A2 (pt) 2015-10-20
BRPI0913590B1 BRPI0913590B1 (pt) 2021-07-06

Family

ID=41397926

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0913590-1A BRPI0913590B1 (pt) 2008-06-03 2009-06-02 Composto de uracila ou sal do mesmo tendo uma atividade inibitória de deoxiuridina trifosfatase humana, composição farmacêutica e inibidor dutpase que compreendem o dito composto de uracila e uso terapêutico do mesmo

Country Status (21)

Country Link
US (1) US8530490B2 (pt)
EP (1) EP2295414B1 (pt)
JP (1) JP4688975B2 (pt)
KR (1) KR101384940B1 (pt)
CN (1) CN102056905B (pt)
AU (1) AU2009254656B2 (pt)
BR (1) BRPI0913590B1 (pt)
CA (1) CA2726579C (pt)
CY (1) CY1113244T1 (pt)
DK (1) DK2295414T3 (pt)
ES (1) ES2392220T3 (pt)
HK (1) HK1154385A1 (pt)
HR (1) HRP20120820T1 (pt)
MX (1) MX2010013275A (pt)
MY (1) MY149180A (pt)
PL (1) PL2295414T3 (pt)
PT (1) PT2295414E (pt)
RU (1) RU2495873C2 (pt)
SI (1) SI2295414T1 (pt)
TW (1) TWI466871B (pt)
WO (1) WO2009147843A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2906227T3 (es) * 2009-11-30 2022-04-13 Taiho Pharmaceutical Co Ltd Potenciador de efecto antitumoral
AU2012234259A1 (en) * 2011-03-31 2013-10-03 Libera-Korner, Jeanette Perfluorinated compounds for the non-viral transfer of nucleic acids
US9809571B2 (en) 2013-01-07 2017-11-07 University Of Southern California Deoxyuridine triphosphatase inhibitors
WO2015103489A1 (en) 2014-01-03 2015-07-09 University Of Southern California Heteroatom containing deoxyuridine triphosphatase inhibitors
US20180110780A1 (en) * 2015-04-30 2018-04-26 Taiho Pharmaceutical Co., Ltd. Agent for alleviating side effect of antitumor drug
MY185785A (en) * 2015-05-01 2021-06-08 Taiho Pharmaceutical Co Ltd Novel crystal of uracil compound
WO2017006283A1 (en) 2015-07-08 2017-01-12 Cv6 Therapeutics (Ni) Limited Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage
WO2017006270A1 (en) * 2015-07-08 2017-01-12 University Of Southern California Deoxyuridine triphosphatase inhibitors
WO2017006271A1 (en) 2015-07-08 2017-01-12 University Of Southern California Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage
JP6836589B2 (ja) 2015-07-08 2021-03-03 シーブイ6 セラピューティクス (エヌアイ) リミテッド ヒダントインを含むデオキシウリジントリホスファターゼ阻害剤
MA43590A (fr) 2016-01-08 2018-11-14 Taiho Pharmaceutical Co Ltd Agent antitumoral contenant un immunomodulateur et un amplificateur d'effet antitumoral
US11014924B2 (en) 2016-11-23 2021-05-25 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
US10858344B2 (en) 2016-11-23 2020-12-08 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
WO2018098208A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Nitrogen ring linked deoxyuridine triphosphatase inhibitors
US11174271B2 (en) 2016-11-23 2021-11-16 Cv6 Therapeutics (Ni) Limited 6-membered uracil isosteres
WO2018098209A1 (en) * 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Amino sulfonyl compounds
WO2018128720A1 (en) * 2017-01-05 2018-07-12 Cv6 Therapeutics (Ni) Limited Uracil containing compounds
US20230263773A1 (en) 2020-06-26 2023-08-24 Cv6 Therapeutics (Ni) Limited Combination therapy with deoxyuridine triphosphatase inhibitors
CN111763176A (zh) * 2020-07-10 2020-10-13 常州制药厂有限公司 一种GnRH受体拮抗剂关键中间体及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4341161A1 (de) 1993-12-02 1995-06-08 Michael Prof Dr Zeppezauer Membrangängiger Wirkstoff zur Störung der DNA-Biosynthese
AU681321B2 (en) * 1995-03-29 1997-08-21 Taiho Pharmaceutical Co., Ltd. Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same
RU2102390C1 (ru) * 1996-06-06 1998-01-20 Научно-исследовательская лаборатория иммунохимиотерапии лепры и иммунотропных средств с клиникой и опытно-экспериментальным производством МЗМП России N-(6-метил-2,4-диоксо-1,2,3,4-тетрагидропиримидинил-5-сульфонил) пиразин-2-карбоксамид, обладающий противолепрозной, противотуберкулезной и иммунотропной активностью, способ его получения
JP2002028486A (ja) * 2000-07-14 2002-01-29 Toyobo Co Ltd アルデヒド類吸着分解剤及びその製造方法
JP2002284686A (ja) 2001-03-28 2002-10-03 Sankyo Co Ltd スルホンアミド化合物を含有する医薬組成物
AU2003218933A1 (en) 2002-04-17 2003-11-03 Affinium Pharmaceuticals, Inc. Purified dutpase from helicobacter pylori
GB0219896D0 (en) 2002-08-27 2002-10-02 Bayer Ag Dihydropyridine derivatives
JP4534122B2 (ja) * 2003-12-26 2010-09-01 トヨタ自動車株式会社 ハイブリッドシステム
GB0400290D0 (en) * 2004-01-08 2004-02-11 Medivir Ab dUTPase inhibitors
BRPI0714880A2 (pt) * 2006-07-24 2013-05-21 Gilead Sciences Inc inibidores da transcriptase reversa do hiv
ES2906227T3 (es) * 2009-11-30 2022-04-13 Taiho Pharmaceutical Co Ltd Potenciador de efecto antitumoral

Also Published As

Publication number Publication date
HRP20120820T1 (hr) 2012-11-30
KR20110013427A (ko) 2011-02-09
EP2295414A1 (en) 2011-03-16
MX2010013275A (es) 2011-03-15
CN102056905A (zh) 2011-05-11
MY149180A (en) 2013-07-31
EP2295414A4 (en) 2011-09-14
CY1113244T1 (el) 2016-04-13
DK2295414T3 (da) 2012-10-22
BRPI0913590B1 (pt) 2021-07-06
JP4688975B2 (ja) 2011-05-25
AU2009254656A2 (en) 2011-01-13
US20110082163A1 (en) 2011-04-07
JPWO2009147843A1 (ja) 2011-10-27
KR101384940B1 (ko) 2014-04-11
RU2010154425A (ru) 2012-07-20
PL2295414T3 (pl) 2013-02-28
HK1154385A1 (en) 2012-04-20
WO2009147843A1 (ja) 2009-12-10
EP2295414B1 (en) 2012-09-26
CA2726579C (en) 2015-02-17
ES2392220T3 (es) 2012-12-05
PT2295414E (pt) 2012-11-30
TW201000452A (en) 2010-01-01
US8530490B2 (en) 2013-09-10
AU2009254656A1 (en) 2009-12-10
CA2726579A1 (en) 2009-12-10
RU2495873C2 (ru) 2013-10-20
AU2009254656B2 (en) 2013-07-18
CN102056905B (zh) 2014-03-26
SI2295414T1 (sl) 2012-12-31
TWI466871B (zh) 2015-01-01

Similar Documents

Publication Publication Date Title
BRPI0913590A2 (pt) novos compostos de uracila ou sal dos mesmos tendo uma atividade inibitória deoxiuridina trifosfatase humana
DE602006010476D1 (de) Implantierbares Herzdiagnosesystem
FR2921499B1 (fr) Structure orientable de type catheter ou endoscope
CY2015024I2 (el) Παραγωγα ινδολιδονης για την θεραπεια ή προληψη ινωτικων ασθενειων
BRPI0818201A2 (pt) Composto de azolcarboxamida ou sal do mesmo
EP2182877A4 (en) DETECTION OF ELASTICITY OF THE CARDIAC TISSUE
BRPI0814624A2 (pt) Tratamento de doença neurodegenerativa progresiva com ibudilaste
BRPI0909662A2 (pt) sistema de monitoração cardíaca estanque à água
BRPI0813425A2 (pt) Junção de sangria
BRPI0820568A2 (pt) Composto, composição farmacêutica, uso de um composto ou uma composição farmacêutica, e, método de tratamento de um humano ou animal
FR2893255B1 (fr) Site medical implantable atraumatique de construction simplifiee
BRPI0718313A2 (pt) Conjunto de cateter
ATE521378T1 (de) Katheter für herzfunktionshilfe
BRPI0917567A2 (pt) tratamento de doença respiratória
BRPI0812632A2 (pt) de compostos de efluente aquoso"
ZA201005210B (en) Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity
BRPI0720220A2 (pt) Derivados de quinolinas antibacterianos
FR2935455B1 (fr) Construction de garniture d'etancheite extensible
DE602006016764D1 (de) Medizinisches Telemetriesystem
BRPI0812359A2 (pt) Derivado de tetra-hidroisoquinolin-1-ona ou sal do mesmo
DK1838318T3 (da) Anvendelse af oxycodon til behandling af visceral smerte
BRPI0914121A2 (pt) derivado de triazol ou sal do mesmo
FR2937531B1 (fr) Systeme d'osteosynthese rachidienne
FI20095600A (fi) Koostumus ihosairauksien hoitoa varten
BRPI1011822A2 (pt) "compostos de 3-substituída-8-substituída-3h-imidazo[5,1-d][1,2,3,5-tetrazin-4-ona e sua aplicação"

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/06/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.